Published in JAMA on July 25, 2007
Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation (2011) 31.98
Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation (2012) 30.79
Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2013) 28.02
Sudden cardiac death prediction and prevention: report from a National Heart, Lung, and Blood Institute and Heart Rhythm Society Workshop. Circulation (2010) 2.94
Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. JAMA (2009) 1.75
A contemporary European experience with surgical septal myectomy in hypertrophic cardiomyopathy. Eur Heart J (2012) 1.64
Diffuse myocardial fibrosis in hypertrophic cardiomyopathy can be identified by cardiovascular magnetic resonance, and is associated with left ventricular diastolic dysfunction. J Cardiovasc Magn Reson (2012) 1.18
Hypertrophic cardiomyopathy: from genetics to treatment. Eur J Clin Invest (2010) 1.17
The ubiquitin-proteasome system and nonsense-mediated mRNA decay in hypertrophic cardiomyopathy. Cardiovasc Res (2009) 1.16
Contemporary treatment of hypertrophic cardiomyopathy. Tex Heart Inst J (2009) 1.12
Update on hypertrophic cardiomyopathy and a guide to the guidelines. Nat Rev Cardiol (2016) 1.11
Prevalence and clinical correlates of QT prolongation in patients with hypertrophic cardiomyopathy. Eur Heart J (2011) 1.11
Hypertrophic cardiomyopathy in 2012. Circulation (2012) 0.98
Primary prevention with the ICD in clinical practice: not as straightforward as the guidelines suggest? Neth Heart J (2009) 0.90
The missing spade: apical hypertrophic cardiomyopathy investigation. Int J Cardiovasc Imaging (2008) 0.90
Experimental therapies in hypertrophic cardiomyopathy. J Cardiovasc Transl Res (2009) 0.90
Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy. Eur Heart J (2010) 0.89
Economic evaluation of strategies to reduce sudden cardiac death in young athletes. Pediatrics (2012) 0.89
Electrocardiographic amplitudes: a new risk factor for sudden death in hypertrophic cardiomyopathy. Eur Heart J (2009) 0.89
High signal intensity on T2-weighted cardiac magnetic resonance imaging correlates with the ventricular tachyarrhythmia in hypertrophic cardiomyopathy. Heart Vessels (2012) 0.87
Hypertrophic cardiomyopathy in childhood. Heart Fail Clin (2010) 0.86
Global longitudinal strain and left atrial volume index improve prediction of appropriate implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy patients. Int J Cardiovasc Imaging (2014) 0.84
Hypertrophic Cardiomyopathy Registry: The rationale and design of an international, observational study of hypertrophic cardiomyopathy. Am Heart J (2015) 0.84
A potential role for integrin signaling in mechanoelectrical feedback. Prog Biophys Mol Biol (2012) 0.84
Hypertrophic cardiomyopathy: diagnosis, risk stratification and treatment. CMAJ (2012) 0.80
The transition to value-based care. J Interv Card Electrophysiol (2016) 0.78
Myocardial Fibrosis in Hypertrophic Cardiomyopathy Demonstrated by Integrated Cardiac F-18 FDG PET/MR. Nucl Med Mol Imaging (2013) 0.78
Long-term follow-up of children and adolescents diagnosed with hypertrophic cardiomyopathy: risk factors for adverse arrhythmic events. Pediatr Cardiol (2011) 0.78
[The ICD as primary prevention. Rare indications]. Herzschrittmacherther Elektrophysiol (2010) 0.78
The risk of non-sustained ventricular tachycardia after percutaneous alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy. Clin Res Cardiol (2010) 0.77
Cardiovascular health, part 1: preparticipation cardiovascular screening. Sports Health (2009) 0.77
Implanted defibrillators in young hypertrophic cardiomyopathy patients: a multicenter study. Pediatr Cardiol (2013) 0.76
[Primary and secondary prophylactic ICD therapy in congenital electrical and structural cardiomyopathies]. Herzschrittmacherther Elektrophysiol (2015) 0.76
Sleep-disordered breathing in hypertrophic cardiomyopathy: challenges and opportunities. Chest (2014) 0.76
Hypertrophic cardiomyopathy and sudden cardiac death. World J Cardiol (2010) 0.76
[ICD therapy in the primary prevention of sudden cardiac death: Risk stratification and patient selection]. Herzschrittmacherther Elektrophysiol (2015) 0.76
Low occurrence of ventricular arrhythmias after alcohol septal ablation in high-risk patients with hypertrophic obstructive cardiomyopathy. Clin Res Cardiol (2016) 0.76
Insights and challenges in hypertrophic cardiomyopathy, 2012. Herzschrittmacherther Elektrophysiol (2012) 0.75
ICD Therapy for Primary Prevention in Hypertrophic Cardiomyopathy. Arrhythm Electrophysiol Rev (2016) 0.75
Shared decision-making in HCM. Nat Rev Cardiol (2017) 0.75
Percutaneous Septal Ablation in Hypertrophic Obstructive Cardiomyopathy: From Experiment to Standard of Care. Adv Med (2014) 0.75
Sudden cardiac death in patients with nonischemic cardiomyopathy. Indian Heart J (2014) 0.75
Disease-specific cardiovascular positron emission tomography/magnetic resonance imaging: a brief review of the current literature. Quant Imaging Med Surg (2016) 0.75
HRS policy statement: clinical cardiac electrophysiology fellowship curriculum: update 2011. Heart Rhythm (2011) 0.75
Device therapy: a subcutaneous ICD--preliminary results. Nat Rev Cardiol (2010) 0.75
Exercise, heart and health. Korean Circ J (2011) 0.75
Hypertrophic cardiomyopathy, sudden death, and implantable cardiac defibrillators: how low the bar? JAMA (2007) 0.75
Safety profile and utility of treadmill exercise in patients with high-gradient hypertrophic cardiomyopathy. Am Heart J (2016) 0.75
Inpatient detection of cardiac-inherited disease: the impact of improving family history taking. Open Heart (2016) 0.75
Clinical Characteristics and Treatment of Cardiomyopathies in Children. Curr Cardiol Rev (2016) 0.75
Diagnostic and prognostic roles of echocardiography and cardiac magnetic resonance. J Nucl Cardiol (2016) 0.75
Myocardial energy depletion and dynamic systolic dysfunction in hypertrophic cardiomyopathy. Nat Rev Cardiol (2016) 0.75
Termination of ventricular tachycardia with antitachycardia pacing after ineffective shock therapy in an ICD recipient with hypertrophic cardiomyopathy. Indian Pacing Electrophysiol J (2009) 0.75
Prognosis of apical hypertrophic cardiomyopathy. JAMA (2007) 0.75
Apical hypertrophic cardiomyopathy presenting as recurrent unexplained syncope. Clin Med Res (2011) 0.75
Comparison of Outcomes in Patients With Nonobstructive, Labile-Obstructive, and Chronically Obstructive Hypertrophic Cardiomyopathy. Am J Cardiol (2015) 0.75
Device therapy in children: current indications. Indian Pacing Electrophysiol J (2008) 0.75
The Role of Cardiac MRI in the Diagnosis and Risk Stratification of Hypertrophic Cardiomyopathy. Arrhythm Electrophysiol Rev (2016) 0.75
The Challenges of Living With an Implantable Cardioverter Defibrillator: A Qualitative Study. Iran Red Crescent Med J (2016) 0.75
Asymptomatic young man with Danon disease. Tex Heart Inst J (2014) 0.75
Sudden cardiac arrest in apical hypertrophic cardiomyopathy. BMJ Case Rep (2009) 0.75
Sudden Cardiac Death: A Review Focused on Cardiovascular Imaging. J Cardiovasc Echogr (2017) 0.75
Septal myectomy after failed septal alcohol ablation. Ann Cardiothorac Surg (2017) 0.75
[A rare cause of syncope in a patient treated with the TASH procedure]. Herzschrittmacherther Elektrophysiol (2010) 0.75
Implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: an updated systematic review and meta-analysis of outcomes and complications. Ann Cardiothorac Surg (2017) 0.75
Combined epicardial and transvenous placement of an implantable cardioverter defibrillator (ICD) lead without a median sternotomy in an 8-year-old child. Pediatr Cardiol (2012) 0.75
Alcohol septal ablation: in which patients and why? Ann Cardiothorac Surg (2017) 0.75
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med (2002) 27.55
Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med (2009) 12.44
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 10.24
Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med (2012) 8.84
Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med (2004) 7.12
Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation (2010) 6.71
Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med (2007) 6.58
Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation (2010) 5.89
Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med (2003) 5.17
2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation (2013) 5.02
Early failure of a small-diameter high-voltage implantable cardioverter-defibrillator lead. Heart Rhythm (2007) 4.96
Part 1: executive summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation (2010) 4.59
Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. Circulation (2009) 4.57
Percutaneous Implantation of an Entirely Intracardiac Leadless Pacemaker. N Engl J Med (2015) 4.26
HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst (2007) 4.14
Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria. Eur Heart J (2010) 4.13
Efficacy and safety of automatic remote monitoring for implantable cardioverter-defibrillator follow-up: the Lumos-T Safely Reduces Routine Office Device Follow-up (TRUST) trial. Circulation (2010) 4.07
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation (2004) 4.04
Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol (2009) 3.89
Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation (2006) 3.82
Survival with cardiac-resynchronization therapy in mild heart failure. N Engl J Med (2014) 3.80
Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation (2008) 3.77
Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med (2005) 3.71
2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 3.63
2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg (2014) 3.59
Long-term progression and outcomes with aging in patients with lone atrial fibrillation: a 30-year follow-up study. Circulation (2007) 3.57
Ventricular pacing or dual-chamber pacing for sinus-node dysfunction. N Engl J Med (2002) 3.35
Postural orthostatic tachycardia syndrome: the Mayo clinic experience. Mayo Clin Proc (2007) 3.32
Diagnostic accuracy of computed tomographic colonography for the detection of advanced neoplasia in individuals at increased risk of colorectal cancer. JAMA (2009) 3.27
A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol (2010) 3.24
Natural history and expansive clinical profile of stress (tako-tsubo) cardiomyopathy. J Am Coll Cardiol (2010) 3.21
Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. Circulation (2010) 3.17
N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J Am Coll Cardiol (2005) 3.12
False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin-tazobactam. Clin Infect Dis (2004) 3.06
Implantable cardioverter defibrillator in high-risk long QT syndrome patients. J Cardiovasc Electrophysiol (2003) 3.05
Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation (2004) 3.03
Arrhythmogenic right ventricular cardiomyopathy/dysplasia clinical presentation and diagnostic evaluation: results from the North American Multidisciplinary Study. Heart Rhythm (2009) 2.82
Prevalence and clinical profile of myocardial crypts in hypertrophic cardiomyopathy. Circ Cardiovasc Imaging (2012) 2.76
ACC/AHA/HRS 2008 guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: executive summary. Heart Rhythm (2008) 2.75
Long-term outcomes of out-of-hospital cardiac arrest after successful early defibrillation. N Engl J Med (2003) 2.68
Adverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine. Mayo Clin Proc (2002) 2.67
Commotio cordis. N Engl J Med (2010) 2.67
Effectiveness of remote monitoring of CIEDs in detection and treatment of clinical and device-related cardiovascular events in daily practice: the HomeGuide Registry. Europace (2013) 2.65
Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. Haematologica (2005) 2.64
Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation (2004) 2.63
Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). Circulation (2011) 2.56
Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation (2003) 2.56
Intermediate-signal-intensity late gadolinium enhancement predicts ventricular tachyarrhythmias in patients with hypertrophic cardiomyopathy. Circ Cardiovasc Imaging (2011) 2.54
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2011) 2.53
Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy? Circulation (2006) 2.52
2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol (2011) 2.48
Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol (2005) 2.43
Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval. J Clin Oncol (2009) 2.38
Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant (2006) 2.37
Recommendations for interpretation of 12-lead electrocardiogram in the athlete. Eur Heart J (2009) 2.37
Association of air pollution with increased incidence of ventricular tachyarrhythmias recorded by implanted cardioverter defibrillators. Environ Health Perspect (2005) 2.36
Syncope while driving: clinical characteristics, causes, and prognosis. Circulation (2009) 2.30
Trans-septal catheterization in the electrophysiology laboratory: data from a multicenter survey spanning 12 years. J Am Coll Cardiol (2006) 2.30
Left ventricular lead position and clinical outcome in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT) trial. Circulation (2011) 2.26
Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J Am Coll Cardiol (2012) 2.25
2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2012) 2.23